Status:
WITHDRAWN
Study to Measure and Enhance the Health Related Quality Of Life in Cancer Patients
Lead Sponsor:
University Health Network, Toronto
Collaborating Sponsors:
Dacima Software Inc.
Conditions:
Cancer
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The ME-Q study aims to validate a patient reported outcome tool called FACT-ICM, which measures health related quality of life (HRQOL) in patients receiving immune checkpoint modulator (ICM) therapy. ...
Detailed Description
Immunotherapy has revolutionized cancer care by extending survival, but with a unique set of toxicities known as immune-related adverse events (irAEs), less is known about impact of ICMs on HRQOL. Th...
Eligibility Criteria
Inclusion
- Age ≥ 18
- Diagnosed with advanced, incurable solid tumors
- Eligible for immunotherapy (monotherapy or combination ICM)
- Life expectancy ≥ 6 months
- ECOG PS 0-3
- Fluent in English
- Able to provide informed consent
- Able to complete questionnaires using digital device or web based application
Exclusion
- Participation in a therapeutic clinical trial testing anticancer therapies
- Receiving adjuvant immunotherapy
Key Trial Info
Start Date :
January 1 2023
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2025
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT05248425
Start Date
January 1 2023
End Date
October 1 2025
Last Update
February 8 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Princess Margaret Cancer Centre
Toronto, Ontario, Canada, M5G 2C1